Anti-TAZ monoclonal antibody
Pre-made anti-TAZ monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to TAZ/TAZ products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP1886-Ab-1/ GM-Tg-hg-IP1886-Ab-2 | Anti-Human TAZ monoclonal antibody | Human |
GM-Tg-rg-IP1886-Ab-1/ GM-Tg-rg-IP1886-Ab-2 | Anti-Rat TAZ monoclonal antibody | Rat |
GM-Tg-mg-IP1886-Ab-1/ GM-Tg-mg-IP1886-Ab-2 | Anti-Mouse TAZ monoclonal antibody | Mouse |
GM-Tg-cynog-IP1886-Ab-1/ GM-Tg-cynog-IP1886-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TAZ monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP1886-Ab-1/ GM-Tg-felg-IP1886-Ab-2 | Anti-Feline TAZ monoclonal antibody | Feline |
GM-Tg-cang-IP1886-Ab-1/ GM-Tg-cang-IP1886-Ab-2 | Anti-Canine TAZ monoclonal antibody | Canine |
GM-Tg-bovg-IP1886-Ab-1/ GM-Tg-bovg-IP1886-Ab-2 | Anti-Bovine TAZ monoclonal antibody | Bovine |
GM-Tg-equg-IP1886-Ab-1/ GM-Tg-equg-IP1886-Ab-2 | Anti-Equine TAZ monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP1886-Ab-1/ GM-Tg-hg-IP1886-Ab-2; GM-Tg-rg-IP1886-Ab-1/ GM-Tg-rg-IP1886-Ab-2; GM-Tg-mg-IP1886-Ab-1/ GM-Tg-mg-IP1886-Ab-2; GM-Tg-cynog-IP1886-Ab-1/ GM-Tg-cynog-IP1886-Ab-2; GM-Tg-felg-IP1886-Ab-1/ GM-Tg-felg-IP1886-Ab-2; GM-Tg-cang-IP1886-Ab-1/ GM-Tg-cang-IP1886-Ab-2; GM-Tg-bovg-IP1886-Ab-1/ GM-Tg-bovg-IP1886-Ab-2; GM-Tg-equg-IP1886-Ab-1/ GM-Tg-equg-IP1886-Ab-2 |
Products Name | Anti-TAZ monoclonal antibody |
Format | mab |
Target Name | TAZ |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-TAZ monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP1886-Ag-1 | Recombinant multi-species TAZ/ BTHS/ CMD3A protein |
ORF Viral Vector | vGMAD000588 | human TAZ Adenovirus particle |
ORF Viral Vector | vGMLP000972 | human TAZ Lentivirus particle |
ORF Viral Vector | pGMAD000588 | human TAZ Adenovirus plasmid |
ORF Viral Vector | pGMLP000972 | human TAZ Lentivirus plasmid |
Target information
Target ID | GM-IP1886 |
Target Name | TAZ |
Gene ID | 6901,66826,363521,574297,119868552,101084092,515177,100058306 |
Gene Symbol and Synonyms | 5031411C02Rik,9130012G04Rik,BTHS,CMD3A,EFE,EFE2,G4.5,LVNCX,TAFAZZIN,TAZ,Taz1 |
Uniprot Accession | Q16635,Q6IV77 |
Uniprot Entry Name | TAZ_HUMAN,TAZ_MACMU |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000102125 |
Target Classification | N/A |
The target: TAZ, gene name: TAZ, also named as BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX, Taz1. This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.